The impact of approved anti-obesity medications on osteoarthritis.

Baser O, Rodchenko K, Vivier E, Baser I, Lu Y, Mohamed M

Expert opinion on pharmacotherapy12 Aug 2024Cited by 14 (Europe PMC)

PMID39129529DOI10.1080/14656566.2024.2391524PepBankPUB-39129529

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity, tirzepatide was associated with significantly lower osteoarthritis risk than semaglutide.
In plain wordsIn adults with obesity, tirzepatide users had lower osteoarthritis risk than semaglutide users. This is a link, not proof of cause.
Peptide
Tirzepatide
Outcome
DecreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Hazard ratio
0.57 ratio
tirzepatide vs semaglutide
Source sentences
Summary
Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
Report a problemFND-3912952904
02HumanObservational studyEfficacy outcome
In adults with obesity, semaglutide was associated with significantly higher osteoarthritis risk than tirzepatide.
In plain wordsIn adults with obesity, semaglutide users had higher osteoarthritis risk than tirzepatide users. This is a link, not proof of cause.
Peptide
Semaglutide
Outcome
IncreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
Tirzepatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Hazard ratio
0.57 ratio
tirzepatide vs semaglutide
Source sentences
Summary
Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
Report a problemFND-3912952905
03HumanObservational studyEfficacy outcome
In adults with obesity, liraglutide was linked to significantly higher osteoarthritis risk than tirzepatide.
In plain wordsIn adults with obesity, liraglutide users had higher osteoarthritis risk than tirzepatide users. This is a link, not proof of cause.
Peptide
Liraglutide
Outcome
IncreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
Tirzepatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Hazard ratio
1.63 ratio
liraglutide vs tirzepatide
Source sentences
Summary
Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
Report a problemFND-3912952906
04HumanObservational studyEfficacy outcome
In adults with obesity, tirzepatide was associated with significantly lower osteoarthritis risk than liraglutide.
In plain wordsIn adults with obesity, tirzepatide users had lower osteoarthritis risk than liraglutide users. This is a link, not proof of cause.
Peptide
Tirzepatide
Outcome
DecreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Hazard ratio
1.63 ratio
liraglutide vs tirzepatide
Source sentences
Summary
Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, p = 0.0007).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
Report a problemFND-3912952907

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

05HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults with obesity, pooled anti-obesity medication use (including tirzepatide) was associated with 27% lower adjusted osteoarthritis risk than non-use.
In plain wordsIn adults with obesity, people using weight-loss drugs as a group had lower osteoarthritis risk than non-users. This is a link, not proof of cause.
Peptide
Tirzepatide
Outcome
DecreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
No AOM use
Outcome group
Bone and joint · Musculoskeletal
Measurements
Risk reduction
27%
AOM users vs non-users
Source sentences
Summary
The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3912952901
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled anti-obesity medication use (including semaglutide) was associated with 27% lower adjusted osteoarthritis risk than non-use.
In plain wordsIn adults with obesity, people using weight-loss drugs as a group had lower osteoarthritis risk than non-users. This is a link, not proof of cause.
Peptide
Semaglutide
Outcome
DecreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
No AOM use
Outcome group
Bone and joint · Musculoskeletal
Measurements
Risk reduction
27%
AOM users vs non-users
Source sentences
Summary
The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3912952902
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with obesity, pooled anti-obesity medication use (including liraglutide) was associated with 27% lower adjusted osteoarthritis risk than non-use.
In plain wordsIn adults with obesity, people using weight-loss drugs as a group had lower osteoarthritis risk than non-users. This is a link, not proof of cause.
Peptide
Liraglutide
Outcome
DecreaseOsteoarthritis risk
Study
n: not reported in source
Comparator
No AOM use
Outcome group
Bone and joint · Musculoskeletal
Measurements
Risk reduction
27%
AOM users vs non-users
Source sentences
Summary
The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3912952903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.